Search
serelaxin
Indications:
- acute heart failure
Dosage:
- infusion 30 ug/kg/day (48 hours) [1]
Mechanism of action:
- recombinant human relaxin-2
- vasodilator
Clinical trials:
[1]
- some beneficial effect on dyspnea in selected patients
- lower 180 day mortality (7.2% vs 11.2% for placebo)
Interactions
drug adverse effects of antihypertensive agents
General
recombinant protein; chimer
vasodilator agent
References
- Teerlink JR et al.
Serelaxin, recombinant human relaxin-2, for treatment of
acute heart failure (RELAX-AHF): A randomised, placebo-
controlled trial.
Lancet 2012 Nov 7
PMID: 23141816
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61855-8/fulltext
- Konstam MA.
RELAX-AHF: Rising from the doldrums in acute heart failure.
Lancet 2012 Nov 7
PMID: 23141815
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61896-0/fulltext